CanSino Biologics (HKG: 6185) up 18% - New power in global pharma market

CanSino Biologics (HKG: 6185) (OTCPK: CASBF) shares are up 18% on Wednesday in Hong Kong. What interests us here is whether this is a signal of an underlying change in the global pharma market. This is to think about the underlying tectonic plates that is, not about the current quarterly results of the varied companies in the market. 

As some background. CanSino is a Canadian and Chinese joint venture-ish company working on vaccines. Of course in recent times vaccine research and production has been very much in the news and for some at least wildly profitable. CanSinoBio has recently had an mRNA vaccine for Covid for example. Akin to the Janssen (aka J&J) one with certain advantages like not requiring deep refrigeration, allowing wider distribution in poorer places. 

The original work was focused on an Ebola vaccine using much the same basic underlying tech. There’s also been much work on inhaled rather than injected vaccines.  

Our interest here is a little different - can we see CanSino as a marker of a major change in the underlying operation of the global pharma market? 

r

CanSino Biologics share price from Google Finance

The thing that interests us here is that China now approves pharmaceuticals. Well, obviously they approve themselves. But it’s possible that this is one of those major changes in the global market. For, until really very recently, a drug which didn’t get approved by the FDA for use in the US didn’t really have a market. Partly because Europe tended to follow FDA decisions and partly because a very large portion of the global pharma spend was in the US. 

And that’s the thing we think might be changing. 20 years ago China’s 1.3 billion people were poor - not far ahead of India. Now they’re not poor - not far behind substantial parts of Europe. And, as we’ve already said, there are 1.3 billion of them. 1.3 billion not-poor people might be a large enough market to support pharmaceutical development without any contribution from the American market at all. Oh, sure, FDA approval would still be nice, the American pharma spend is massive after all. But it’s no longer, perhaps, necessary. 

It’s that, we think, which might be one of those very large underlying changes in the global market that we need to be aware of. It is at least possible that the US FDA is no longer the sole determinant of whether a drug can be successfully marketed. And that is a really big change if it’s true.